{"entity":{"id":"nct03386513","kind":"trial","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","aka":[],"tldr":"A phase 1/2 trial of Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm and myeloproliferative neoplasms, run by AbbVie, active and no longer recruiting.","summary":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN is a phase 1/2 interventional study registered as NCT03386513 by AbbVie, with 179 participants enrolled, started 2018-01-02 and due to reach its primary completion in 2024-10-02. Interventions recorded: IMGN632. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03386513","url":"https://clinicaltrials.gov/study/NCT03386513"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["bpdcn","myeloproliferative-neoplasms"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["pivekimab-sunirine"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03386513","phase":"1/2","setting":"A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies","sponsor":"AbbVie","started":"2018-01-02","startedType":"actual","yearReported":2026,"enrolled":179,"enrolledBasis":"registry","outcomes":[{"endpoint":"Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants","primary":true,"unit":"%","arms":[{"name":"Frontline De Novo BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg","n":22,"value":72.7,"note":"95% CI 49.78 to 89.27; Figures from the ClinicalTrials.gov results section (first posted 2026-09-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT03386513?tab=results"},{"endpoint":"Overall Survival in Total R/R BPDCN Participants","unit":"months","arms":[{"name":"Total R/R BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg","n":51,"value":5.78,"note":"95% CI 3.943 to 8.378; Figures from the ClinicalTrials.gov results section (first posted 2026-09-04), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT03386513?tab=results"}]},"route":"/trials/nct03386513/","neighbours":{"cancer":[{"id":"bpdcn","kind":"cancer","name":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","route":"/cancers/bpdcn/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}